首頁 > 市場調查報告書 > 製藥

非專利藥生技仿製藥

市場調查報告書

商品編碼

1688856

生物相似藥：全球市場

Biosimilars: Global Markets

出版日期: 2025年03月18日 | 出版商:

BCC Research | 英文 219 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

全球生物相似藥市場規模預計將從 2023 年的 238 億美元和 2024 年的 285 億美元成長到 2029 年的 692 億美元，預測期內的複合年成長率為 19.4%。

預計歐洲生物相似藥市場規模將從 2024 年的 130 億美元成長到 2029 年的 316 億美元，預測期內的複合年成長率為 19.4%。北美生物相似藥市場預計將從 2024 年的 92 億美元成長到 2029 年的 229 億美元，複合年成長率為 20.1%。

本報告調查了全球生物相似藥市場，並提供了市場概況的摘要、市場影響因素和市場機會的分析、法律制度、新興技術和技術發展的趨勢、市場規模的趨勢和預測、各個細分市場和地區的詳細分析、競爭格局以及主要企業的概況。

細分市場
全球生物相似藥市場按產品類型分類
單株抗體
重組生長因子
重組激素
融合蛋白
其他
全球生物相似藥市場（依治療用途分類）
癌症及相關疾病
自體免疫和發炎性疾病
糖尿病
貧血
生長激素缺乏
其他
地理分佈
全球生物相似藥市場按地區分類
市場規模及預測
北美洲
歐洲
亞太地區
其他地區

第6章競爭格局及專利分析

概述
主要市場領導
新興企業
戰略分析
問題和未來趨勢
專利分析
有利於品牌生技藥品的專利監管
市場獨佔性

第7章監管方面

概述
歐洲
美國
排他性原則
中國

第 8 章全球生物相似藥市場的永續性：ESG 視角

ESG：簡介
市場中的 ESG 表現
生物相似藥產業的 ESG 實踐
環境績效
BCC的結語

第 9 章附錄

調查方法
來源
簡稱
公司簡介
ACCORD BIOPHARMA INC.
ALVOTECH
AMGEN INC.
AMNEAL PHARMACEUTICALS LLC.
BIOCON BIOLOGICS LTD.
BIOGEN
CELLTRION INC.
COHERUS BIOSCIENCES
FRESENIUS KABI AG
LILLY
PFIZER INC.
SAMSUNG BIOEPIS
SANDOZ GROUP AG
TEVA PHARMACEUTICAL INDUSTRIES LTD.
VIATRIS INC.

簡介目錄圖表

Product Code: BIO090E

The global biosimilars market was valued at $23.8 billion in 2023. The market is expected to grow from $28.5 billion in 2024 to $69.2 billion by 2029, at a compound annual growth rate (CAGR) of 19.4% from 2024 through 2029.

The European biosimilars market is expected to grow from $13.0 billion in 2024 to $31.6 billion by 2029, at a CAGR of 19.4% from 2024 through 2029.

The North American biosimilars market is expected to grow from $9.2 billion in 2024 to $22.9 billion by 2029, at a CAGR of 20.1% from 2024 through 2029.

Report Scope

This report provides the current and future market potential of biosimilars, with market projections through 2029; and it includes a detailed analysis of the drivers, restraints and opportunities in the biosimilars market. The report also covers the competitive environment of the biosimilars industry and features a product analysis.

For this analysis, the market for biosimilars is segmented based on product type, therapeutic application and region. Based on product type, it is segmented into monoclonal antibodies, recombinant growth factors, recombinant hormones, fusion protein and others (such as LMWHs and interferons). Based on therapeutic application, the market is segmented into the following: cancer and related disorders, autoimmune and inflammatory diseases, diabetes, anemia, growth hormone deficiency and other diseases. Based on geographical region, the biosimilars market is segmented into the following: North America, Europe, Asia-Pacific and the Rest of the World (RoW). The North American region includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., Italy, France, Spain and the Rest of Europe; Asia-Pacific includes China, Japan, India, Australia, South Korea and the Rest of Asia-Pacific. For market estimate data, 2021 and 2022 serve as the historical years, 2023 as the base year, and 2029 as the forecast year.

The report provides company profiles of key players in the biosimilars market that feature detailed information about each organization's business segments, financials, product portfolios and recent developments.

Report Includes

142 data tables and 74 additional tables
An analysis of the global market trends for biosimilars, with historic revenue data (sales figures) from 2021 and 2022, estimates for 2023, forecast for 2024, and projected CAGRs through 2029
Estimates of the market size and revenue growth prospects, along with a market share analysis by product type and sub-type, therapeutic application, and region
Facts and figures pertaining to the market dynamics, advances in existing biosimilars, regulations and the impact of macroeconomic factors
Review of the industry structure, emerging trends and developments, clinical trials and approvals, and new product
Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses
An analysis of key patent publications, grants and applications in biosimilars
Analysis of the competitive landscape featuring companies' market shares, strategic alliances, M&A activity and a venture funding outlook
Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and ESG scores and practices of leading companies
Profiles of the market leaders, including Amgen Inc., Sandoz Group AG, Biocon Biologics Ltd., Pfizer Inc., and Teva Pharmaceutical Industries Ltd.

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Insights

Chapter 2 Market Overview

Introduction
Terminology of Biosimilars
Key Terms in Biosimilars
WHO Guidelines on Evaluation of Biosimilars
Pharmacovigilance/Post-Approval Monitoring
Biosimilars Vs. Biobetters
Popular Types of Biosimilars
Recombinant Hormones
Recombinant Growth Factors
Monoclonal Antibodies (mAbs)
Fusion Proteins
Interferons
Low Molecular Weight Heparins (LMWHs)

Chapter 3 Market Dynamics

Introduction
Market Drivers
Patent Expirations of Major Biologics
Cost-effectiveness and Healthcare Savings
Market Restraints
Intellectual Property and Legal Issues
Manufacturing and Supply Chain Complexities
Market Opportunities
Increasing Access, Adoption and Awareness
Emerging Markets

Chapter 4 Emerging Technologies

Advanced Analytical Techniques
Single-use Bioreactors
Cell Line Engineering and Expression Systems

Chapter 5 Market Segmentation Analysis

Segmentation Breakdown
Global Biosimilars Market, by Product Type
Monoclonal Antibodies
Recombinant Growth Factors
Recombinant Hormones
Fusion Protein
Others
Global Biosimilars Market, by Therapeutic Application
Cancer and Related Disorders
Autoimmune and Inflammatory Diseases
Diabetes
Anemia
Growth Hormone Deficiency
Other Diseases
Geographic Breakdown
Global Biosimilars Market, by Region
Market Size and Forecast
North America
Europe
Asia-Pacific
Rest of the World (RoW)

Chapter 6 Competitive Landscape and Patent Analysis

Overview
Key Market Leaders
Emerging Players
Strategic Analysis
Challenges and Future Trends
Patent Analysis
Patent Regulations in Favor of Branded Biologics
Market Exclusivity

Chapter 7 Regulatory Aspects

Overview
Biosimilar Regulations in Europe
Biosimilar Regulations in the U.S.
Principle of Exclusivity
Biosimilar Regulations in China

Chapter 8 Sustainability in the Global Biosimilars Market: An ESG Perspective

Introduction to ESG
ESG Performance in the Market
ESG Practices in the Biosimilars Industry
Environmental Performance
Concluding Remarks from BCC Research

Chapter 9 Appendix

Research Methodology
Sources
Abbreviations
Company Profiles
ACCORD BIOPHARMA INC.
ALVOTECH
AMGEN INC.
AMNEAL PHARMACEUTICALS LLC.
BIOCON BIOLOGICS LTD.
BIOGEN
CELLTRION INC.
COHERUS BIOSCIENCES
FRESENIUS KABI AG
LILLY
PFIZER INC.
SAMSUNG BIOEPIS
SANDOZ GROUP AG
TEVA PHARMACEUTICAL INDUSTRIES LTD.
VIATRIS INC.

簡介目錄圖表

List of Tables

Summary Table : Global Biosimilars Market, by Region, Through 2029
Table 1 : Differences Between Generic and Biosimilar Drugs
Table 2 : Terminology Related to Biosimilars
Table 3 : Biosimilars Vs. Biobetters
Table 4 : Examples of Approved Biobetters
Table 5 : Representative Biobetters in Clinical Trials
Table 6 : Key Developments in Biosimilar Recombinant Hormones
Table 7 : Key Developments in Biosimilar Recombinant Growth Factors
Table 8 : Key Developments in Biosimilar Monoclonal Antibodies
Table 9 : Key Developments in Enbrel (Etanercept) Biosimilars
Table 10 : Key Developments in Biosimilar Interferons
Table 11 : Key Developments in LMWHs Biosimilars
Table 12 : Global Biosimilars Market, by Product Type, Through 2029
Table 13 : EMA Approved Biosimilar Monoclonal Antibodies
Table 14 : FDA Approved Biosimilar Monoclonal Antibodies
Table 15 : Global Biosimilar Monoclonal Antibodies Market, by Region, Through 2029
Table 16 : Global Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 17 : Global Trastuzumab Biosimilars Market, by Region, Through 2029
Table 18 : Global Rituximab Biosimilars Market, by Region, Through 2029
Table 19 : Global Adalimumab Biosimilars Market, by Region, Through 2029
Table 20 : Global Bevacizumab Biosimilars Market, by Region, Through 2029
Table 21 : Global Infliximab Biosimilars Market, by Region, Through 2029
Table 22 : EMA Approved Recombinant Growth Factors Biosimilars
Table 23 : FDA Approved Recombinant Growth Factors Biosimilars
Table 24 : Global Recombinant Growth Factors Biosimilars Market, by Region, Through 2029
Table 25 : Global Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 26 : Global Filgrastim Biosimilars Market, by Region, Through 2029
Table 27 : Global Epoetin Alfa Biosimilars Market, by Region, Through 2029
Table 28 : Global Pegfilgrastim Biosimilars Market, by Region, Through 2029
Table 29 : EMA Approved Recombinant Hormones Biosimilars
Table 30 : FDA Approved Recombinant Hormones Biosimilars
Table 31 : Global Recombinant Hormones Biosimilars Market, by Region, Through 2029
Table 32 : Global Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 33 : Global Insulin Biosimilars Market, by Region, Through 2029
Table 34 : Global Somatotropin Biosimilars Market, by Region, Through 2029
Table 35 : Global Teriparatide Biosimilars Market, by Region, Through 2029
Table 36 : Global Follitropin Alfa Biosimilars Market, by Region, Through 2029
Table 37 : Global Fusion Protein Biosimilars Market, by Region, Through 2029
Table 38 : Global Other Biosimilars Market, by Region, Through 2029
Table 39 : Global Biosimilars Market, by Therapeutic Application, Through 2029
Table 40 : Global Cancer and Related Disorders Market in Biosimilars, by Region, Through 2029
Table 41 : Global Autoimmune and Inflammatory Diseases Market in Biosimilars, by Region, Through 2029
Table 42 : Global Diabetes Market in Biosimilars, by Region, Through 2029
Table 43 : Global Anemia Market in Biosimilars, by Region, Through 2029
Table 44 : Global Growth Hormone Deficiency Market in Biosimilars, by Region, Through 2029
Table 45 : Global Other Diseases Market in Biosimilars, by Region, Through 2029
Table 46 : Global Biosimilars Market, by Region, Through 2029
Table 47 : North American Biosimilars Market, by Country, Through 2029
Table 48 : North American Biosimilars Market, by Product Type, Through 2029
Table 49 : North American Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 50 : North American Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 51 : North American Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 52 : North American Biosimilars Market, by Therapeutic Application, Through 2029
Table 53 : Biosimilar Approvals in the U.S.
Table 54 : U.S. Biosimilars Market, by Product Type, Through 2029
Table 55 : U.S. Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 56 : U.S. Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 57 : U.S. Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 58 : U.S. Biosimilars Market, by Therapeutic Application, Through 2029
Table 59 : Canadian Biosimilars Market, by Product Type, Through 2029
Table 60 : Canadian Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 61 : Canadian Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 62 : Canadian Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 63 : Canadian Biosimilars Market, by Therapeutic Application, Through 2029
Table 64 : Mexican Biosimilars Market, by Product Type, Through 2029
Table 65 : Mexican Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 66 : Mexican Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 67 : Mexican Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 68 : Mexican Biosimilars Market, by Therapeutic Application, Through 2029
Table 69 : Biosimilar Approvals in Europe
Table 70 : European Biosimilars Market, by Country, Through 2029
Table 71 : European Biosimilars Market, by Product Type, Through 2029
Table 72 : European Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 73 : European Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 74 : European Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 75 : European Biosimilars Market, by Therapeutic Application, Through 2029
Table 76 : German Biosimilars Market, by Product Type, Through 2029
Table 77 : German Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 78 : German Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 79 : German Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 80 : German Biosimilars Market, by Therapeutic Application, Through 2029
Table 81 : U.K. Biosimilars Market, by Product Type, Through 2029
Table 82 : U.K. Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 83 : U.K. Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 84 : U.K. Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 85 : U.K. Biosimilars Market, by Therapeutic Application, Through 2029
Table 86 : French Biosimilars Market, by Product Type, Through 2029
Table 87 : French Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 88 : French Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 89 : French Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 90 : French Biosimilars Market, by Therapeutic Application, Through 2029
Table 91 : Italian Biosimilars Market, by Product Type, Through 2029
Table 92 : Italian Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 93 : Italian Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 94 : Italian Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 95 : Italian Biosimilars Market, by Therapeutic Application, Through 2029
Table 96 : Spanish Biosimilars Market, by Product Type, Through 2029
Table 97 : Spanish Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 98 : Spanish Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 99 : Spanish Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 100 : Spanish Biosimilars Market, by Therapeutic Application, Through 2029
Table 101 : Rest of European Biosimilars Market, by Product Type, Through 2029
Table 102 : Rest of European Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 103 : Rest of European Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 104 : Rest of European Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 105 : Rest of European Biosimilars Market, by Therapeutic Application, Through 2029
Table 106 : Asia-Pacific Biosimilars Market, by Country, Through 2029
Table 107 : Asia-Pacific Biosimilars Market, by Product Type, Through 2029
Table 108 : Asia-Pacific Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 109 : Asia-Pacific Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 110 : Asia-Pacific Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 111 : Asia-Pacific Biosimilars Market, by Therapeutic Application, Through 2029
Table 112 : Biosimilar Approvals in China
Table 113 : Chinese Biosimilars Market, by Product Type, Through 2029
Table 114 : Chinese Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 115 : Chinese Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 116 : Chinese Recombinant Hormones Biosimilars, by Product Type, Through 2029
Table 117 : Chinese Biosimilars Market, by Therapeutic Application, Through 2029
Table 118 : Japanese Biosimilars Market, by Product Type, Through 2029
Table 119 : Japanese Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 120 : Japanese Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 121 : Japanese Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 122 : Japanese Biosimilars Market, by Therapeutic Application, Through 2029
Table 123 : Indian Biosimilars Market, by Product Type, Through 2029
Table 124 : Indian Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 125 : Indian Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 126 : Indian Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 127 : Indian Biosimilars Market, by Therapeutic Application, Through 2029
Table 128 : Australian Biosimilars Market, by Product Type, Through 2029
Table 129 : Australian Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 130 : Australian Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 131 : Australian Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 132 : Australian Biosimilars Market, by Therapeutic Application, Through 2029
Table 133 : South Korean Biosimilars Market, by Product Type, Through 2029
Table 134 : South Korean Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 135 : South Korean Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 136 : South Korean Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 137 : South Korean Biosimilars Market, by Therapeutic Application, Through 2029
Table 138 : Rest of Asia-Pacific Biosimilars Market, by Product Type, Through 2029
Table 139 : Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 140 : Rest of Asia-Pacific Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 141 : Rest of Asia-Pacific Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 142 : Rest of Asia-Pacific Biosimilars Market, by Therapeutic Application, Through 2029
Table 143 : RoW Biosimilars Market, by Product Type, Through 2029
Table 144 : RoW Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 145 : RoW Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 146 : RoW Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 147 : RoW Biosimilars Market, by Therapeutic Application, Through 2029
Table 148 : Select Strategic Alliances in the Biosimilars Industry, 2022-2024
Table 149 : Leading Biosimilars Companies, by Revenue, 2023
Table 150 : U.S. Patent Expirations and Biosimilars, 2024
Table 151 : Pending Biosimilar Patent Litigation, 2024
Table 152 : FDA Guidelines on Biosimilars, February 2021
Table 153 : Biosimilar Products Approved in China, 2024
Table 154 : Key Focus Areas in ESG Metrics
Table 155 : ESG Rankings for Key Players in Biosimilars Market, 2024*
Table 156 : Information Sources in This Report
Table 157 : Glossary of Terms Used in the Biosimilars Market
Table 158 : Accord BioPharma Inc.: Company Snapshot
Table 159 : Accord BioPharma Inc.: Product Portfolio
Table 160 : Accord BioPharma Inc.: News/Key Developments, 2024
Table 161 : Alvotech: Company Snapshot
Table 162 : Alvotech: Financial Performance, FY 2022 and 2023
Table 163 : Alvotech: Product Portfolio
Table 164 : Alvotech: News/Key Developments, 2024
Table 165 : Amgen Inc.: Company Snapshot
Table 166 : Amgen Inc.: Financial Performance, FY 2022 and 2023
Table 167 : Amgen Inc.: Product Portfolio
Table 168 : Amgen Inc.: News/Key Developments, 2022-2023
Table 169 : Amneal Pharmaceuticals LLC.: Company Snapshot
Table 170 : Amneal Pharmaceuticals LLC.: Financial Performance, FY 2022 and 2023
Table 171 : Amneal Pharmaceuticals LLC.: Product Portfolio
Table 172 : Amneal Pharmaceuticals LLC.: News/Key Developments, 2023-2024
Table 173 : Biocon Biologics Ltd.: Company Snapshot
Table 174 : Biocon Biologics Ltd.: Financial Performance, FY 2022 and 2023
Table 175 : Biocon Biologics Ltd.: Product Portfolio
Table 176 : Biocon Biologics Ltd.: News/Key Developments, 2022-2024
Table 177 : Biogen: Company Snapshot
Table 178 : Biogen: Financial Performance, FY 2022 and 2023
Table 179 : Biogen: Product Portfolio
Table 180 : Biogen: News/Key Developments, 2023-2024
Table 181 : Celltrion Inc.: Company Snapshot
Table 182 : Celltrion Inc.: Financial Performance, FY 2022 and 2023
Table 183 : Celltrion Inc.: Product Portfolio
Table 184 : Celltrion Inc.: News/Key Developments, 2023-2024
Table 185 : Coherus BioSciences: Company Snapshot
Table 186 : Coherus BioSciences: Financial Performance, FY 2022 and 2023
Table 187 : Coherus BioSciences: Product Portfolio
Table 188 : Coherus BioSciences: News/Key Developments, 2024
Table 189 : Fresenius Kabi AG: Company Snapshot
Table 190 : Fresenius Kabi AG: Financial Performance, FY 2022 and 2023
Table 191 : Fresenius Kabi AG: Product Portfolio
Table 192 : Fresenius Kabi AG: News/Key Developments, 2024
Table 193 : Lilly: Company Snapshot
Table 194 : Lilly: Financial Performance, FY 2022 and 2023
Table 195 : Lilly: Product Portfolio
Table 196 : Lilly: News/Key Developments, 2022-2023
Table 197 : Pfizer Inc.: Company Snapshot
Table 198 : Pfizer Inc.: Financial Performance, FY 2022 and 2023
Table 199 : Pfizer Inc.: Product Portfolio
Table 200 : Pfizer Inc.: News/Key Developments, 2023
Table 201 : Samsung Bioepis: Company Snapshot
Table 202 : Samsung Bioepis: Product Portfolio
Table 203 : Samsung Bioepis: News/Key Developments, 2023-2024
Table 204 : Sandoz Group AG: Company Snapshot
Table 205 : Sandoz Group AG: Financial Performance, FY 2022 and 2023
Table 206 : Sandoz Group AG: Product Portfolio
Table 207 : Sandoz Group AG: News/Key Developments, 2024
Table 208 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 209 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2022 and 2023
Table 210 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 211 : Teva Pharmaceutical Industries Ltd.: News/Key Developments, 2023-2024
Table 212 : Viatris Inc.: Company Snapshot
Table 213 : Viatris Inc.: Financial Performance, FY 2022 and 2023
Table 214 : Viatris Inc.: Product Portfolio
Table 215 : Viatris Inc.: News/Key Developments, 2022

List of Figures

Summary Figure : Share of Global Market for Biosimilars, by Region, 2023
Figure 1 : Snapshot of the Market Dynamics for Biosimilars
Figure 2 : Share of Global Market for Biosimilars, by Product Type, 2023
Figure 3 : Global Biosimilar Monoclonal Antibodies Market, by Region, 2021-2029
Figure 4 : Global Recombinant Growth Factors Biosimilars Market, by Region, 2021-2029
Figure 5 : Global Recombinant Hormones Biosimilars Market, by Region, 2021-2029
Figure 6 : Global Fusion Protein Biosimilars Market, by Region, 2021-2029
Figure 7 : Global Other Biosimilars Market, by Region, 2021-2029
Figure 8 : Share of Global Market for Biosimilars, by Therapeutic Application, 2023
Figure 9 : Global Cancer and Related Disorders Market in Biosimilars, 2021-2029
Figure 10 : Global Cancer and Related Disorders Market in Biosimilars, by Region, 2021-2029
Figure 11 : Global Autoimmune and Inflammatory Diseases Market in Biosimilars, 2021-2029
Figure 12 : Global Autoimmune and Inflammatory Diseases Market in Biosimilars, by Region, 2021-2029
Figure 13 : Global Diabetes Market in Biosimilars, 2021-2029
Figure 14 : Global Diabetes Market in Biosimilars, by Region, 2021-2029
Figure 15 : Global Anemia Market in Biosimilars, 2021-2029
Figure 16 : Global Anemia Market in Biosimilars, by Region, 2021-2029
Figure 17 : Global Growth Hormone Deficiency Market in Biosimilars, 2021-2029
Figure 18 : Global Growth Hormone Deficiency Market in Biosimilars, by Region, 2021-2029
Figure 19 : Global Other Diseases Market in Biosimilars, 2021-2029
Figure 20 : Global Other Diseases Market in Biosimilars, by Region, 2021-2029
Figure 21 : Share of Global Market for Biosimilars, by Region, 2023
Figure 22 : Global Biosimilars Market, by Region, 2021-2029
Figure 23 : Share of North American Market for Biosimilars, by Country, 2023
Figure 24 : U.S. Biosimilars Market, 2021-2029
Figure 25 : Canadian Biosimilars Market, 2021-2029
Figure 26 : Mexican Biosimilars Market, 2021-2029
Figure 27 : Share of European Market for Biosimilars, by Country, 2023
Figure 28 : German Biosimilars Market, 2021-2029
Figure 29 : U.K. Biosimilars Market, 2021-2029
Figure 30 : French Biosimilars Market, 2021-2029
Figure 31 : Italian Biosimilars Market, 2021-2029
Figure 32 : Spanish Biosimilars Market, 2021-2029
Figure 33 : Rest of European Biosimilars Market, 2021-2029
Figure 34 : Share of Asia-Pacific Market for Biosimilars, by Country, 2023
Figure 35 : Chinese Biosimilars Market, 2021-2029
Figure 36 : Japanese Biosimilars Market, 2021-2029
Figure 37 : Indian Biosimilars Market, 2021-2029
Figure 38 : Australian Biosimilars Market, 2021-2029
Figure 39 : South Korean Biosimilars Market, 2021-2029
Figure 40 : Rest of Asia-Pacific Biosimilars Market, 2021-2029
Figure 41 : Snapshot of the ESG Pillars
Figure 42 : Advantages of ESG for Biosimilar Companies
Figure 43 : Share of Biotech Companies Providing ESG Disclosure, 2022
Figure 44 : Share of ESG Disclosure, by Location, 2022
Figure 45 : Alvotech: Revenue Share, by Country/Region, FY 2023
Figure 46 : Amgen Inc.: Revenue Share, by Country/Region, FY 2023
Figure 47 : Amneal Pharmaceuticals LLC.: Revenue Share, by Business Unit, FY 2023
Figure 48 : Biocon Biologics Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 49 : Biocon Biologics Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 50 : Biogen: Revenue Share, by Business Unit, FY 2023
Figure 51 : Biogen: Revenue Share, by Country/Region, FY 2023
Figure 52 : Fresenius Kabi AG: Revenue Share, by Business Unit, FY 2023
Figure 53 : Lilly: Revenue Share, by Business Unit, FY 2023
Figure 54 : Lilly: Revenue Share, by Country/Region, FY 2023
Figure 55 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2023
Figure 56 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2023
Figure 57 : Sandoz Group AG: Revenue Share, by Business Unit, FY 2023
Figure 58 : Sandoz Group AG: Revenue Share, by Country/Region, FY 2023
Figure 59 : Teva Pharmaceutical Industries Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 60 : Viatris Inc.: Revenue Share, by Business Unit, FY 2023
Figure 61 : Viatris Inc.: Revenue Share, by Country/Region, FY 2023